Top shape
Back

Nuage has joined AseBio, the Spanish BioIndustry Association, which brings together biotech companies and organisations across Spain

News
June 2025

As part of joining AseBio, they have interviewed our CEO, Stuart Hughes. You can see the full interview below.

  • What does your company’s work bring to the table and what is its strength?

Nuage’s mission is to usher in a new wave of transformational precision therapies for aggressive cancers with limited treatment options. By pioneering a novel drug discovery approach, we directly target the oncogenic transcription factors that drive cancer progression, shutting down key disease pathways that have remained inaccessible to conventional drug discovery.

Nuage ultimately aims to become the preeminent company in the intrinsically disordered protein (IDP) target space, leveraging its technology beyond oncology into other therapeutic areas where protein disorder plays a key role and treatment options remain limited.

Nuage also brings together a highly skilled team of professionals with international experience gained at world-leading institutions and research centres. 


“We see AseBio as the go-to platform for fostering synergies within Spain’s biotech sector. It provides essential tools and activities to connect startups with investors and industry leaders, an invaluable resource and asset for a company like ours“

Stuart Hugues, CEO

  • When did you first hear about AseBio?

One of our founding investors, Asabys, is a long-standing member of AseBio and they recommended that we join to enjoy the benefits of a country-wide network of like-minded companies and individuals. 

  • What is Asebio for you?

We see AseBio as the go-to platform for fostering synergies within Spain’s biotech sector. It provides essential tools and activities to connect startups with investors and industry leaders, an invaluable resource and asset for a company like ours.

  • What do you expect from being part of an association like AseBio?

We believe that being a member of AseBio will give us access to a strong network of key stakeholders within the Spanish biotech sector. It will also help us raise our profile in the industry through its activities while leveraging our interests within the different working groups. 

Participating in these working groups will also be of incredible value, as it enables us to help shape and influence the future of our sector in Spain. 

  • What is the biggest challenge facing the biotech sector or your company?

We are part of a fast-growing and dynamic ecosystem. However, securing sustainable funding across all stages of development can be challenging, especially for early-stage companies. It is therefore especially important to foster synergies between startups, investors, public funding agencies, and pharmaceutical companies in order to advance in this sector while making the best use of limited resources. 

You can also find the interview in Spanish on AseBio’s website.